STOCKWATCH: Will cancer info dump ruffle markets?
This article was originally published in Scrip
The big news at the European Cancer Congress in Amsterdam this weekend was not down to any one particular pharma company's good or bad clinical results. It was simply that all the news from the Congress was released at the same time as the organizers lifted all the embargos on presentations at the meeting. That meant that a bolus of potential market-moving and market-sensitive material was released over the weekend when no trading was taken place, rather than being staggered over the course of the Congress.